Avaliação de parâmetros metabólicos em homens transgêneros durante o tratamento com testosterona em ambulatório referência do SUS.

Abstract

Transsexuality is defined as a discordance between biological sex and gender identity. In Brazil, one of the available treatments to align gender with identity in transgender men is hormone therapy with testosterone. As with any other hormonal therapy, besides the desired results, adverse effects may occur that can put users at risk. Among the changes observed in previous studies, androgenic hormones can modify metabolic parameters correlated with cardiovascular risk, such as hematocrit, LDL, and HDL. Consequently, the objective of this study is to analyze the metabolic parameters of transgender men at the reference outpatient clinic of the SUS in the State of Sergipe, at the Federal University of Sergipe, Lagarto Campus, which provides hormonal treatment for these individuals. This study is a retrospective cohort of transgender men undergoing testosterone therapy, analyzing medication usage time, weight, height, BMI, systolic and diastolic blood pressure, total cholesterol, LDL and HDL, triglycerides, fasting glucose, glycated hemoglobin, hemoglobin, and hematocrit before testosterone use and at the last hormone therapy consultation. An increase was observed in weight by 7.2% (71.9 ± 14.8 to 77.1 ± 12.5 kg, p = 0.04), total cholesterol by 17.7% (141.2 ± 22.7 to 166.2 ± 27.2 mg/dl, p = 0.04), LDL by 26.9% (75.0 ± 17.4 to 95.2 ± 13.6 mg/dl, p = 0.01), hemoglobin by 19.2% (13.0 ± 1.2 to 15.5 ± 1.3 g/dl, p = 0.01), and hematocrit by 16.8% (39.9 ± 3.8 to 46.6 ± 4.9%, p = 0.03) in individuals undergoing testosterone treatment for approximately 20.1 ± 11.9 months.The long-term significance of these findings is yet to be determined, but they suggest the need for attention to cardiovascular safety in this group. More studies, particularly on the long-term use of testosterone, are necessary.